Neha Kaul1, Joshua Laing1, John-Paul Nicolo1, Judy Nation1, Patrick Kwan1, Terence J O'Brien1. 1. Department of Allied Health (Clinical Nutrition) (NK), Royal Melbourne Hospital; Department of Nutrition and Dietetics, (NK) Alfred Hospital; Departments of Medicine and Neurology (NK, J-PN, JN, PK, TJO), Royal Melbourne Hospital, University of Melbourne; and Departments of Neurosciences and Neurology (NK, JL, J-PN, PK, TJO), Alfred Hospital and Monash University, Melbourne, Australia.
Abstract
PURPOSE OF REVIEW: Ketogenic diet therapy can be used as an adjuvant treatment of super-refractory status epilepticus (SRSE). However, the drug and metabolic interactions with concomitant treatments present a challenge for clinicians. In this review, we focus on the practical considerations of implementing ketogenic dietary therapy in the acute setting, including the dietary composition, potential drug-diet interactions, and monitoring during ketogenic treatment. RECENT FINDINGS: This report describes the ketogenic diet therapy protocol implemented for the treatment of SRSE and a review of the current evidence to support clinical practice. SUMMARY: The control of SRSE is critical in reducing morbidity and mortality. There is emerging evidence that ketogenic diet may be a safe and effective treatment option for these patients.
PURPOSE OF REVIEW: Ketogenic diet therapy can be used as an adjuvant treatment of super-refractory status epilepticus (SRSE). However, the drug and metabolic interactions with concomitant treatments present a challenge for clinicians. In this review, we focus on the practical considerations of implementing ketogenic dietary therapy in the acute setting, including the dietary composition, potential drug-diet interactions, and monitoring during ketogenic treatment. RECENT FINDINGS: This report describes the ketogenic diet therapy protocol implemented for the treatment of SRSE and a review of the current evidence to support clinical practice. SUMMARY: The control of SRSE is critical in reducing morbidity and mortality. There is emerging evidence that ketogenic diet may be a safe and effective treatment option for these patients.
Authors: Stephen A McClave; Beth E Taylor; Robert G Martindale; Malissa M Warren; Debbie R Johnson; Carol Braunschweig; Mary S McCarthy; Evangelia Davanos; Todd W Rice; Gail A Cresci; Jane M Gervasio; Gordon S Sacks; Pamela R Roberts; Charlene Compher Journal: JPEN J Parenter Enteral Nutr Date: 2016-02 Impact factor: 4.016
Authors: Tracy Glauser; Shlomo Shinnar; David Gloss; Brian Alldredge; Ravindra Arya; Jacquelyn Bainbridge; Mary Bare; Thomas Bleck; W Edwin Dodson; Lisa Garrity; Andy Jagoda; Daniel Lowenstein; John Pellock; James Riviello; Edward Sloan; David M Treiman Journal: Epilepsy Curr Date: 2016 Jan-Feb Impact factor: 7.500
Authors: Paul Vespa; Meral Tubi; Jan Claassen; Manuel Buitrago-Blanco; David McArthur; Angela G Velazquez; Bin Tu; Mayumi Prins; Marc Nuwer Journal: Ann Neurol Date: 2016-02-28 Impact factor: 10.422
Authors: Dafna Sussman; Matthijs van Eede; Michael D Wong; Susan Lee Adamson; Mark Henkelman Journal: BMC Pregnancy Childbirth Date: 2013-05-08 Impact factor: 3.007
Authors: Eric H Kossoff; Beth A Zupec-Kania; Stéphane Auvin; Karen R Ballaban-Gil; A G Christina Bergqvist; Robyn Blackford; Jeffrey R Buchhalter; Roberto H Caraballo; J Helen Cross; Maria G Dahlin; Elizabeth J Donner; Orkide Guzel; Rana S Jehle; Joerg Klepper; Hoon-Chul Kang; Danielle A Lambrechts; Y M Christiana Liu; Janak K Nathan; Douglas R Nordli; Heidi H Pfeifer; Jong M Rho; Ingrid E Scheffer; Suvasini Sharma; Carl E Stafstrom; Elizabeth A Thiele; Zahava Turner; Maria M Vaccarezza; Elles J T M van der Louw; Pierangelo Veggiotti; James W Wheless; Elaine C Wirrell Journal: Epilepsia Open Date: 2018-05-21